U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Нeparin (or Unfractionated heparin ) is an anticoagulant indicated for both the prevention and treatment of thrombotic events such as deep vein thrombosis (DVT) and pulmonary embolism (PE) as well as atrial fibrillation (AF). Heparin can also be used to prevent excess coagulation during procedures such as cardiac surgery, extracorporeal circulation or dialysis, including continuous renal replacement therapy. Heparin administration can be by intravenous (or subcutaneous route. Intravenous heparin is continuously administered for therapeutic anticoagulation, while intermittent subcutaneous administration is used to prevent thromboembolism. Once administered, heparin binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. The heparin-ATIII complex can also inactivate factors IX, XI, XII, and plasmin, but the antithrombotic effect of heparin is well correlated to the inhibition of factor Xa. Typical adverse effects from heparin use include bleeding, thrombocytopenia, injection site reactions, and other adverse effects only seen with chronic heparin administration. Bleeding is a major complication associated with heparin use. Patients should undergo monitoring for new bleeding that may present in the urine or stool. Bleeding may also present as bruising, petechial rash and nosebleeds.

CNS Activity

Curator's Comment:: The possibility of heparin penetration into brain cells was shown. The penetration occurred apparently in the form of heparin complexes with thromboplastin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
281 nM [Kd]
607 nM [Kd]
106 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HEPARIN SODIUM

Approved Use

Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

Launch Date

69984000000
Primary
HEPARIN SODIUM

Approved Use

Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

Launch Date

69984000000
Primary
HEPARIN SODIUM

Approved Use

Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

Launch Date

69984000000
PubMed

PubMed

TitleDatePubMed

Sample Use Guides

Deep Subcutaneous (Intrafat) Injection:
Route of Administration: Other
Substance Class Polymer
Created
by admin
on Fri Jun 25 21:13:34 UTC 2021
Edited
by admin
on Fri Jun 25 21:13:34 UTC 2021
Record UNII
ZZ45AB24CA
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
HEPARIN SODIUM
EP   INN   MART.   ORANGE BOOK   USP   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
HEPARIN LOCK FLUSH
Brand Name English
SODIUM SALT OF SULPHATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS
Common Name English
PANHEPRIN
Brand Name English
HEPARIN SODIUM [USP]
Common Name English
HEPARIN SODIUM [EP MONOGRAPH]
Common Name English
HEPARIN SODIUM [WHO-IP]
Common Name English
LIPO-HEPIN
Brand Name English
LIQUEMIN SODIUM
Brand Name English
HEPARIN SODIUM [MART.]
Common Name English
SODIUM SALT OF SULFATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS
Common Name English
HEPARIN SODIUM [WHO-DD]
Common Name English
EMBOLEX COMPONENT HEPARIN SODIUM
Common Name English
HEPARIN SODIUM PORCINE
Common Name English
LIQUAEMIN SODIUM
Brand Name English
HEPARIN SODIUM [INN]
Common Name English
SODIUM HEPARIN
INCI  
INCI  
Official Name English
HEPARIN SODIUM, PORCINE
Common Name English
SODIUM HEPARIN [INCI]
Common Name English
S01XA14
Code English
HEPARIN SODIUM [ORANGE BOOK]
Common Name English
LIQUAEMIN LOCK FLUSH
Brand Name English
HEPARIN SODIUM COMPONENT OF EMBOLEX
Common Name English
HEPARIN SODIUM UNFRACTIONATED
Common Name English
HEPARIN SODIUM [VANDF]
Common Name English
HEPARIN SODIUM PORCINE [WHO-DD]
Common Name English
HEPARINUM NATRICUM [WHO-IP LATIN]
Common Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 10.2
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
WHO-ATC C05BA03
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
FDA ORPHAN DRUG 222106
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
FDA ORPHAN DRUG 694019
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
WHO-ATC B01AB01
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
EU-Orphan Drug EU/3/05/337
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
NCI_THESAURUS C263
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL1201657
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
PRIMARY
FDA UNII
ZZ45AB24CA
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
PRIMARY
NCI_THESAURUS
C833
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
HEPARIN SODIUM
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
PRIMARY Description: A white or almost white powder. Solubility: Freely soluble in water. Category: Anticoagulant. Storage: Heparin sodium should be kept in a tightly closed container. Labelling: The designation Heparin sodium for parenteral use indicates that the substance complies with the additional requirements and may be used for parenteral administration. The label should also state the name and quantity of any added substances, and the source of the material (lung or mucosal). Expiry date. Additional information: Heparin sodium is moderately hygroscopic.Definition: Heparin sodium is a preparation containing the sodium salt of a sulfated glucosaminoglycan present in mammalian tissues. It has the characteristic property of delaying the clotting of fresh blood. Heparin sodium intended for the manufacture of a parenteral dosage form contains not less than 150 IU per mg, and Heparin sodium not intended for use in the manufacture of a parenteral dosage form contains not less than 120 IU per mg, both calculated with reference to the dried substance.
RXCUI
314659
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
ALTERNATIVE
RXCUI
9877
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
PRIMARY
DRUG BANK
DBSALT000417
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
PRIMARY
EVMPD
SUB02478MIG
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
PRIMARY
CAS
9041-08-1
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
GENERIC (FAMILY)
INN
392
Created by admin on Fri Jun 25 21:13:34 UTC 2021 , Edited by admin on Fri Jun 25 21:13:34 UTC 2021
PRIMARY
Display Structure of HEPARIN SODIUM
Related Record Type Details
PARENT -> SALT/SOLVATE
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO_ACID_SUBSTITUTION SODIUM CATION LYR4M0NH37
AMINO_ACID_SUBSTITUTION Amount: UNSPECIFIED SUBSTANCE
6fe0b0ee
(not in database)
Name Property Type Amount Referenced Substance Defining Parameters References
DEGREE OF SULFATION PHYSICAL
MOL_WEIGHT:WEIGHT AVERAGE CHEMICAL